Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are.
Shares in Roche Holding AG rose 0.38 percent to close at 184.60 francs on the Zurich exchange Tuesday. In a conference call with reporters, he declined to answer questions about whether Roche might reconsider its failed hostile bid of about $6.5 billion to acquire U.S. diagnostics firm Illumina Inc..
Analyst Sung Ji Nam said that for now, the major sources of growth for companies including Illumina Inc. and Life Technologies Corp. will be sales of new, more advanced gene-sequencing products and disposable items used in testing, and their biggest clients will remain academic and clinical customers.
Cramer makes the call on viewers' favorite stocks.
*Illumina machine turns around diagnosis in two days in pilot study. Stephen Kingsmore, director of the Center for Pediatric Genomic Medicine at Children's Mercy medical center in Kansas City, Missouri, whose study was published in the journal Science Translational Medicine.
**ARQULE INC, $2.30, down 53.9 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **GENERAL MOTORS, $23.82, up 3 pct. Hedge fund manager David Einhorn said auto-maker General Motors "is much healthier now," and is getting its product refreshments "right."
Take a look at some of Tuesday's midday movers:
The Dow and S&P 500 turned negative while the Nasdaq cut its gains in late morning on Tuesday, with materials and energy shares leading declines on the S&P. **ARQULE INC $2.21 down 55.5 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **FORD MOTOR CO, $9.78, down 1.6 pct.
The Nasdaq Composite Index added 14.98 points, or 0.48 percent, to 3,128.51. **ARQULE INC $2.14, down 57.73 pct The biotechnology company and Japan's Daiichi Sankyo Co Ltd. **SIRIUS XM RADIO INC, $2.62, up 2 pct.
NEW YORK, Oct 2- Illumina Inc:.
Allscripts Healthcare Solutions is enacting a shareholder rights plan — or “poison pill” — to help it ward off an opportunistic takeover bid, even before an offer emerges.
Here’s a look at five stocks hedge fund managers hate.
Amylin Pharmaceuticals, which spurned a $3.5 billion takeover bid from Bristol-Myers Squibb and is fending off a lawsuit from activist investor Carl Icahn, started reaching out to potential buyers last week, sources familiar with the situation said on Sunday.
Stocks accelerated their losses in the final minutes of trading to close near lows Wednesday, pressured by a handful of lackluster tech earnings and amid renewed concerns over the euro zone.
The FMHR traders break down their top three trades, including a look at shares of Buffett's Berkshire Hathaway. Also, Rosecliff Capital CEO, Michael Murphy, explains his big bet on mining company Freeport-McMoRan.
U.S. stock index futures were lower Wednesday as central banks seemed to drift away from the idea of injecting more monetary stimulus and European shares fell.
Take a look at some of Wednesday’s morning movers:
Shareholders of all girth face a host of meetings with the pharmaceutical company currently in the crosshairs of a hostile bid from Swiss drug maker Roche.
CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.